February 2015 - The annual Goldman Prize awarded by the iCMLf in honour of Professor John Goldman complements the iCMLf’s Rowley Prize as a clinical equivalent recognising outstanding lifetime contributions to the management of patients with CML. The iCMLf awards the 2015 Goldman Prize to Professor Michele Baccarani in recognition of his over forty years of dedication to clinical excellence in the management of CML.
February 2015 - The iCMLf Rowley Prize is designed to recognise persons who have made major contributions to the understanding of the biology of CML. In 2015 the Rowley Prize is awarded to Professor Richard Van Etten. This iCMLf award recognises Dr Van Etten’s groundbreaking research focusing on the development of new therapeutic strategies such as the tyrosine kinase inhibitors.
September 2014 - We are delighted to present the iCMLf Annual Report 2013/2014. It features the Foundation’s activities from Sept 1st 2013 to August 31st 2014.
Key outcomes from the iCMLf in the last 12 months include:
October 2014 - ‘Patient education is an essential supplement to good professional healthcare.’* With the on going success of TKI therapies and greater numbers of CML patients remaining on treatment, many for life, people who have an interest in self-education will continue to grow. Patient specific educational resources are very valuable and we share two of these with you today. We hope these are useful, not only for our members who are patients and or patient advocates, but also for physicians around the world to share with their patients.
August 2014 - The iCMLf has relaunched its website. Programs, discussions and education on this interactive platform now have a new structure and a fresh new look to make the multi-layered content more accessible. We invite you to see and look for yourself on a tour around the new website.
July 2014 - “We wanted to spread the benefit of new knowledge, effective drugs and accurate monitoring beyond the developed world. This was our first and is still our highest priority”. (Tim Hughes)
Q1: Great advances have been made in the management of patients with CML during the last couple of years. Where do you currently still see the biggest challenges and how could we best meet those challenges?
The outlook for a newly diagnosed CML patient is very positive in 2014 – a complete turnaround from the situation they faced even in the 1990s. However we still see CML patients transform into blast crisis in the first one or two years of kinase inhibitor therapy. We must find ways to identify these patients before they transform and trial innovative approaches. This remains one of our biggest challenges.